Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F14%3A10293159" target="_blank" >RIV/00064203:_____/14:10293159 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/14:10293159
Result on the web
<a href="http://dx.doi.org/10.1016/j.urolonc.2013.07.006" target="_blank" >http://dx.doi.org/10.1016/j.urolonc.2013.07.006</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.urolonc.2013.07.006" target="_blank" >10.1016/j.urolonc.2013.07.006</a>
Alternative languages
Result language
angličtina
Original language name
Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma
Original language description
Objectives: Evidence suggests a positive effect of metfoimin on cancer incidence and outcome. To date, the effect of metfoimin use on prognosis in urothelial carcinoma of the bladder (UCB) remains uninvestigated. We tested the hypothesis that metformin use affects oncologic outcomes of patients treated with radical cystectomy for UCB. Methods and materials: We retrospectively evaluated 1,502 patients treated at 4 institutions with radical cystectomy and pelvic lymphadenectomy without neoadjuvant therapy. Cox regression models addressed the association of diabetes mellitus (DM) and metformin use with disease recurrence, cancer-specific mortality, and any-cause mortality. Results: A total of 200 patients (13.3%) had DM, 80 patients (5.3%) used metformin.Within a median follow-up of 34 months, 509 patients (33.9%) experienced disease recurrence, 402 patients (26.8%) died of UCB, and 551 patients (36.7%) died from any cause. In univariable Cox regression analyses, DM without metfonnin use
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Urologic Oncology: Seminars and Original Investigations
ISSN
1078-1439
e-ISSN
—
Volume of the periodical
32
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
8
Pages from-to
—
UT code for WoS article
000347243300098
EID of the result in the Scopus database
—